Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-M Riedinger

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Breast Cancer Research and Treatment|August 10, 2000
Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancerM Arnal, N Franco, P Fargeot, et al.
Transplantation Proceedings|February 1, 1994
Normal range of [99mTc]MAG-3 renogram parameters in renal transplant recipientsA Riedinger-Berriolo, C Touzery, D Chevet, et al.
International Journal of Cancer|August 7, 1997
Loss of heterozygosity at the TP53 gene: independent occurrence from genetic instability events in node-negative breast cancerS Lizard-Nacol, J M Riedinger, G Lizard, et al.
Bulletin Du Cancer|January 22, 1998
[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time]J M Riedinger, B Coudert, I Barillot, et al.
European Journal of Nuclear Medicine|January 1, 1987
Fourier and factorial analysis: an objective and comparative evaluation on a cardiac phantomP O Kotzki, C Touzery, T Munsch, et al.
Anticancer Research|January 12, 2000
MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patientsS Lizard-Nacol, P Genne, B Coudert, et al.
Colloids and Surfaces. B, Biointerfaces|June 30, 2018
Cellular interactions of functionalized superparamagnetic iron oxide nanoparticles on oligodendrocytes without detrimental side effects: Cell death induction, oxidative stress and inflammationS Sruthi, L Maurizi, T Nury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2012
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypesO Humbert, A Berriolo-Riedinger, J M Riedinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric studyJ M Riedinger, J Wafflart, G Ricolleau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeJ M Riedinger, F Bonnetain, J P Basuyau, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|August 10, 2000
Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancerM Arnal, N Franco, P Fargeot, et al.
Transplantation Proceedings|February 1, 1994
Normal range of [99mTc]MAG-3 renogram parameters in renal transplant recipientsA Riedinger-Berriolo, C Touzery, D Chevet, et al.
International Journal of Cancer|August 7, 1997
Loss of heterozygosity at the TP53 gene: independent occurrence from genetic instability events in node-negative breast cancerS Lizard-Nacol, J M Riedinger, G Lizard, et al.
Bulletin Du Cancer|January 22, 1998
[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time]J M Riedinger, B Coudert, I Barillot, et al.
European Journal of Nuclear Medicine|January 1, 1987
Fourier and factorial analysis: an objective and comparative evaluation on a cardiac phantomP O Kotzki, C Touzery, T Munsch, et al.
Anticancer Research|January 12, 2000
MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patientsS Lizard-Nacol, P Genne, B Coudert, et al.
Colloids and Surfaces. B, Biointerfaces|June 30, 2018
Cellular interactions of functionalized superparamagnetic iron oxide nanoparticles on oligodendrocytes without detrimental side effects: Cell death induction, oxidative stress and inflammationS Sruthi, L Maurizi, T Nury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2012
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypesO Humbert, A Berriolo-Riedinger, J M Riedinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric studyJ M Riedinger, J Wafflart, G Ricolleau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeJ M Riedinger, F Bonnetain, J P Basuyau, et al.
Pageof 3